GlassScriptPhysician profile
Ralph John Cahaly
NPI 1790778553
$30,043.66
in general payments reported to CMS, 2019-2025
42 companies · $5,127 in 2025
The $5,127 reported for 2025 was more than what 86% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $1,919 · 2021: $2,819 · 2022: $3,971 · 2023: $9,846 · 2024: $4,369 · 2025: $5,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $4,625 · Travel and Lodging: $806 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,752.02 |
| Consulting Fee | $4,625.00 |
| Travel and Lodging | $806.33 |
| Education | $158.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,785.40 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $6,475.58 | 2019-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,874.66 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,841.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,378.32 | 2019-2025 | |
| Csl Behring | $1,116.13 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $1,024.04 | 2019-2025 | |
| Amgen INC. | $901.49 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $841.74 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Pharming Healthcare, INC. | $837.74 | 2020-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $780.12 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Blueprint Medicines Corporation | $703.89 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $678.53 | 2021-2025 | Orladeyo |
| Leo Pharma INC. | $545.36 | 2022-2025 | Adbry |
| Teva Pharmaceuticals USA, INC. | $534.44 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $394.33 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.23 | 2019-2023 | Spiriva Respimat |
| Greer Laboratories, INC. | $367.87 | 2019-2024 | Palforzia |
| Genzyme Corporation | $328.91 | 2019-2025 | |
| Octapharma USA, INC. | $288.38 | 2019-2020 | |
| Kaleo, INC. | $277.74 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $210.97 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Circassia INC. | $165.30 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $164.42 | 2025 | Neffy |
| Abbvie INC. | $163.62 | 2022-2023 | Rinvoq |
| Covis Pharma Gmbh | $149.70 | 2021-2023 | |
| Gc Biopharma USA, INC. | $117.01 | 2024-2025 | Alyglo, Alyglo |
| Galderma Laboratories, L.P. | $89.97 | 2025 | Nemluvio |
| Incyte Corporation | $75.26 | 2022-2025 | Opzelura |
| Cycle Pharmaceuticals INC | $71.12 | 2024-2025 | Sajazir |
| Bio Products Laboratory USA, INC. | $67.57 | 2019-2022 | |
| Lilly USA, LLC | $66.10 | 2024-2025 | Ebglyss |
| Kedrion Biopharma, INC. | $59.09 | 2025 | Kedrab, Koate, Gammaked |
| Ionis Pharmaceuticals, INC. | $57.73 | 2025 | Donidalorsen |
| Shire North American Group INC | $55.23 | 2019 | |
| Pulmonx Corporation | $33.09 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Invivyd INC | $32.25 | 2025 | Pemgarda |
| X4 Pharmaceuticals, INC. | $31.03 | 2024 | Xolremdi |
| Biohaven Pharmaceutical Holding Company LTD. | $23.52 | 2022 | |
| Optinose US, INC. | $23.18 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $21.67 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Cahaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.